Therapy optimisation trial for the treatment of non-Hodgkin lymphomas 

Non-Hodgkin lymphomas (NHL) are the fourth most common childhood cancer and are almost always malignant in this age group. The aim of the therapy optimisation trial LBL 2018 is to improve recovery rates and prevent the occurrence of relapses (recurrences).

Background

The term non-Hodgkin lymphoma (NHL) covers a variety of malignant diseases of the lymphatic system. Within the group of NHLs, lymphoblastic lymphomas (LBL) are the second most common subgroup. LBL are cancers in which certain white blood cells, called lymphocytes, turn into cancer cells and no longer perform their tasks in the immune system. Without treatment, these malignant cells will grow unhindered, leading to a life-threatening situation.

Aim of the trial

The current standard treatment for LBL, consisting of a combination of different chemotherapeutic agents, has been used in more or less the same form over the last two decades. With this standard treatment, patients have to accept relevantly high rates of acute side effects and long-term consequences, as chemotherapy also damages healthy tissue. Furthermore, the LBL can recur. In the case of a relapse, the second treatment is very difficult. The findings from the international study are aimed at optimising the therapies used to date. This should improve recovery rates and avoid relapses – particularly in the area of the brain and spinal cord (central nervous system).

Implementing organisation

Swiss Paediatric Oncology Group (SPOG)